Recurrent Glioblastoma Multiforme (GBM) Pipeline Report H1 2016 - Review of 39 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

Introduction

Recurrent Glioblastoma Multiforme (GBM) Overview

Therapeutics Development

Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview

Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis

Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies

Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes

Recurrent Glioblastoma Multiforme (GBM) Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies

Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes

Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development

  • AbbVie Inc.
  • Agenus, Inc.
  • Amgen Inc.
  • AngioChem Inc.
  • Apogenix GmbH
  • AstraZeneca Plc
  • Axelar AB
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cantex Pharmaceuticals, Inc.
  • Cavion LLC
  • Celldex Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Cortice Biosciences, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EnGeneIC Ltd
  • ERC Belgium SA
  • GenSpera, Inc.
  • Genzyme Corporation
  • GW Pharmaceuticals Plc
  • ImmunoCellular Therapeutics, Ltd.
  • Karyopharm Therapeutics, Inc.
  • Les Laboratoires Servier SAS
  • Medicenna Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Oryx GmbH & Co. KG
  • Pfizer Inc.
  • Stemline Therapeutics, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tocagen Inc.

For more information visit http://www.researchandmarkets.com/research/9lzn9k/recurrent

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Brain Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Brain Cancer Drugs